Slide 1: Third Quarter 2012 Earnings Release
Exhibit 99.1 Third Quarter 2012 Earnings Release October 23, 2012
Slide 2: Agenda
Agenda 2 • Strategic Plan Summary (2013 – 2015) • Capital Allocation • Q3 2012 Summary • 2012 Segment Performance Fluid & Metering Health & Science Fire & Safety / Diversified • 2012 Guidance Update • Q&A
Slide 3: Replay Information
Replay Information 3 Dial toll–free: 855.859.2056 International: 404.537.3406 Conference ID: #40918415 Log on to: www.idexcorp.com IDEX Proprietary & Confidential
Slide 4: Cautionary Statement Under the Private Securities Litigation Reform Act
4 Cautionary Statement Under the Private Securities Litigation Reform Act This presentation and discussion will include forward-looking statements. Our actual performance may differ materially from that indicated or suggested by any such statements. There are a number of factors that could cause tho
Slide 5: Strategic Plan Summary (2013-2015)
Strategic Plan Summary (2013 2015) – 5 Consistently deliver double digit earnings growth, exceptional Objective cash conversion and superior return on invested capital. To build global platforms and defensible niches in attractive, Strategy highly engineered markets where we can create a leadership
Slide 6: Capital Allocation
Capital Allocation 6 • IDEX balance sheet and strong cash generation enables strong & consistent total shareholder returns • Over $1.5B to allocate over the next 3 years – Organic investments = always top priority – Dividend = consistent payout ~30% of earnings – Acquisitions = will continue to use
Slide 7: IDEX Q3 2012 Financial Performance
IDEX Q3 2012 Financial Performance 7 Total Revenue EPS* Organic: 1% growth 7% decline Q3 2011 benefited $477 $480 from CEO costs and $1.00 $0.71 $0.66 tax true-up $500 2011 2011 $250 2012 2012 $0 Q3 $0.00 Q3 Operating Margin* Free Cash Flow flat year over year 7% growth $92 20% 18.3% 18.3% $86 19% $
Slide 8: Fluid & Metering
Fluid & Metering 8 Total Orders Total Revenue Operating Margin* Organic: 3% growth Organic: 1% decline 130 bps expansion $206 25% 21.4% $300 $197 $198 $300 $198 20.1% $200 $200 20% $100 $100 15% $0 $0 10% Q3 Q3 Q3 2011 2012 2011 2012 2011 2012 Q3 Sales Mix:Organic -1% Q3 Summary: Energy and Ag marke
Slide 9: Health & Science
Health & Science 9 Total Orders Total Revenue Operating Margin* Organic: 9% decline Organic: 4% decline 150 bps contraction 25% $300 $300 $171 $166 $173 $176 18.8% 20% 17.3% $200 $200 $100 $100 15% $0 $0 10% Q3 Q3 Q3 2011 2012 2011 2012 2011 2012 Q3 Sales Mix:Organic -4% Q3 Summary: Optics & Photoni
Slide 10: Fire & Safety/Diversified
Fire & Safety/Diversified 10 Total Orders Total Revenue Operating Margin* Organic: 7% decline Organic: 13% growth 360 bps expansion $112 $108 30% 24.8% $150 $101 $150 $99 21.2% $100 $100 20% $50 $50 $0 $0 10% Q3 Q3 Q3 2011 2012 2011 2012 2011 2012 Q3 Sales Mix:Organic +13% Q3 Summary: North American
Slide 11: Outlook: 2012 Guidance Summary
Outlook: 2012 Guidance Summary 11 FY 2012 EPS estimate range: $2.65 $2.70 – Organic revenue growth ~ 3% Positive acquisition impact ~ 5% Operating margin ~ 18.5% th Negative Fx impact ~ 2% to sales September (at 30 rates) Other modeling items Tax rate ~ 30% Cap Ex ~ $38M Free Cash Flow will signific
Slide 12: Q&A
12 Q&A IDEX Proprietary & Confidential